

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7939960

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
RICKY WAYNE COUCH	06/08/2021
PETER GREGORY VARLASHKIN	06/08/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CATALENT PHARMA SOLUTIONS
<b>Street Address:</b>	14 SCHOOLHOUSE ROAD
<b>City:</b>	SOMERSET
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08873
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17806821
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)420-2200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2024202200
<b>Email:</b>	patents@blankrome.com, judy.yeddo@blankrome.com
<b>Correspondent Name:</b>	BLANK ROME LLP - II-VI
<b>Address Line 1:</b>	1825 EYE STREET NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20006-5403
<b>ATTORNEY DOCKET NUMBER:</b>	163529-02002
<b>NAME OF SUBMITTER:</b>	JUDY YEDDO
<b>SIGNATURE:</b>	/Judy Yeddo/
<b>DATE SIGNED:</b>	05/07/2023
<b>Total Attachments: 6</b>	
source=Assignment_4#page1.tif	
source=Assignment_4#page2.tif	
source=Assignment_4#page3.tif	
source=Assignment_4#page4.tif	
source=Assignment_4#page5.tif	



## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned Inventors: **Ricky Wayne Couch and Peter Gregory Varlashkin** hereby sell and assign to **Catalent Pharma Solutions**, a corporation formed under the laws of Delaware, whose mailing address is 14 Schoolhouse Road, Somerset, NJ 08873 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-iodo-phenylamino)-benzamide** AND USES THEREOF for which an International PCT application was filed on February 17, 2021 under PCT Application No. PCT/US2021/018381 and for which United States Application No. 17/177,966 was filed on February 17, 2021, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned Inventors had this assignment and sale not been made.

The undersigned Inventors agree to execute all papers necessary in connection with the applications and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination applications thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned Inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the Inventors.

IN WITNESS WHEREOF, executed by the undersigned Inventors on the date opposite his/her name.

Date: 8-June 2021

Signature of Inventor: *Ricky Wayne Couch*

Ricky Wayne COUCH

*Peter Varleshkni*  
Witness Signature

Peter Varleshkni  
Witness Name (Typed or Handwritten)

815 Kimball Drive, Durham, NC 27705  
Witness Address

Date: 8 June 2021

Signature of Inventor: Peter Varlashkin  
Peter Gregory VARLASHKIN

Ricky Wayne Couch  
Witness Signature

Ricky Wayne Couch  
Witness Name (Typed or Handwritten)

1425 Sedwick Road Durham, NC 27713  
Witness Address

SIGNED on behalf of the said ASSIGNEE,

Catalent Pharma Solutions

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_  
Date: \_\_\_\_\_

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Name (Typed or Handwritten)

\_\_\_\_\_  
Witness Address

16331733.1

## ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned Inventors: **Ricky Wayne Couch and Peter Gregory Varlashkin** hereby sell and assign to **Catalent Pharma Solutions**, a corporation formed under the laws of Delaware, whose mailing address is 14 Schoolhouse Road, Somerset, NJ 08873 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYLAMINO)-BENZAMIDE AND USES THEREOF** for which an International PCT application was filed on February 17, 2021 under PCT Application No. PCT/US2021/018381 and for which United States Application No. 17/177,966 was filed on February 17, 2021, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent applications or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned Inventors had this assignment and sale not been made.

The undersigned Inventors agree to execute all papers necessary in connection with the applications and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination applications thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned Inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned Inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the Inventors.

IN WITNESS WHEREOF, executed by the undersigned Inventors on the date opposite his/her name.

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Ricky Wayne COUCH

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Name (Typed or Handwritten)

\_\_\_\_\_  
Witness Address

Date: \_\_\_\_\_ Signature of Inventor: \_\_\_\_\_  
Peter Gregory VARLASHKIN

\_\_\_\_\_  
Witness Signature

\_\_\_\_\_  
Witness Name (Typed or Handwritten)

\_\_\_\_\_  
Witness Address

SIGNED on behalf of the said ASSIGNEE,

Catalent Pharma Solutions

By: Maureen O'Brien

Name: Maureen O'Brien

Title: Attorney-in-Fact

Date: July 6, 2021

Alisha Riddick  
Witness Signature

Alisha Riddick  
Witness Name (Typed or Handwritten)

14 Schoolhouse Road, Somerset, NJ 08873  
Witness Address

July 6, 2021

16331733.1